Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS.

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Abstract Text:

ABSTRACT: BACKGROUND: Angiogenesis is a critical early feature of atherosclerotic plaque development and may also feature prominently in the pathogenesis of aortic valve stenosis. It has been shown that MRI can detect and quantify specific molecules of interest expressed in cardiovascular disease and cancer by measuring the unique fluorine signature of appropriately targeted perfluorocarbon (PFC) nanoparticles. In this study, we demonstrated specific binding of alphanubeta3 integrin targeted nanoparticles to neovasculature in a rabbit model of aortic valve disease. We also showed that fluorine MRI could be used to detect and quantify the development of neovasculature in the excised aortic valve leaflets. METHODS: New Zealand White rabbits consumed a cholesterol diet for ~180 days and developed aortic valve thickening, inflammation, and angiogenesis mimicking early human aortic valve disease. Rabbits (n = 7) were treated with alphanubeta3 integrin targeted PFC nanoparticles or control untargeted PFC nanoparticles (n = 6). Competitive inhibition in vivo of nanoparticle binding (n = 4) was tested by pretreatment with targeted nonfluorinated nanoparticles followed 2 hours later by targeted PFC nanoparticles. 2 hours after treatment, aortic valves were excised and 19F MRS was performed at 11.7T. Integrated 19F spectral peaks were compared using a one-way ANOVA and Hsu's MCB (multiple comparisons with the best) post hoc t test. In 3 additional rabbits treated with alphanubeta3 integrin targeted PFC nanoparticles, 19F spectroscopy was performed on a 3.0T clinical scanner. The presence of angiogenesis was confirmed by immunohistochemistry. RESULTS: Valves of rabbits treated with targeted PFC nanoparticles had 220% more fluorine signal than valves of rabbits treated with untargeted PFC nanoparticles (p < 0.001). Pretreatment of rabbits with targeted oil-based nonsignaling nanoparticles reduced the fluorine signal by 42% due to competitive inhibition, to a level not significantly different from control animals. Nanoparticles were successfully detected in all samples scanned at 3.0T. PECAM endothelial staining and alphanubeta3 integrin staining revealed the presence of neovasculature within the valve leaflets. CONCLUSION: Integrin-targeted PFC nanoparticles specifically detect early angiogenesis in sclerotic aortic valves of cholesterol fed rabbits. These techniques may be useful for assessing atherosclerotic components of preclinical aortic valve disease in patients and could assist in defining efficacy of medical therapies.

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of cardiovascular magnetic resonance : off

VOLUME: 10

Page Numbers: 43

Journal Abbreviation:

ISSN: 1532-429X

DAY: 25

MONTH: 09

YEAR: 2008

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9815616

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS.

AFFILIATION: Department of Medicine, Washington University School of Medicine, St, Louis, MO, USA. saw@howdy.wustl.edu.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Cardiovasc Magn Reson

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS Related Publications

• 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons.
• 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles.
• Contrast agents for MRI.
• Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS.
• Experimental determination of phase velocity of perfluorocarbons: Applications to targeted contrast agents.
• Exploiting lipid raft transport with membrane targeted nanoparticles: A strategy for cytosolic drug delivery.
• High-frequency ultrasound detection of the temporal evolution of protein cross linking in myocardial tissue.
• Molecular Imaging by Cardiovascular MR.
• Nanomedicine opportunities in cardiology.
• Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery.
• Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging.
• Sensitive ultrasonic detection of dystrophic skeletal muscle in patients with duchenne muscular dystrophy using an entropy-based signal receiver.
• Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides.
• Targeted ultrasonic contrast agents for molecular imaging and therapy.
• Thromboembolism in patients undergoing total knee arthroplasty with epidural analgesia.